The complement system contributes to the pathology of experimental autoimmune encephalomyelitis by triggering demyelination and modifying the antigen-specific T and B cell response

Clinical Immunology

Volumn 146, Issue 3, 2013, Pages 155-164

  Hundgeburth, Lorenz C ^a   Wunsch, Marie ^a   Rovituso, Damiano ^a   Recks, Mascha S ^a   Addicks, Klaus ^a   Lehmann, Paul V ^b   Kuerten, Stefanie ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Cellular Technology Limited   (United States)

Author keywords

B cells; Complement; Demyelination; EAE MS; MP4; T cells

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; GAMMA INTERFERON; MYELIN AND LYMPHOCYTE PROTEIN; SNAKE VENOM;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; COMPLEMENT SYSTEM; DEMYELINATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; INTERFERON PRODUCTION; MOUSE; MYELIN SHEATH; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; WILD TYPE;

ANIMALS; ANTIGENS; B-LYMPHOCYTES; COBRA VENOMS; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT SYSTEM PROTEINS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; MICE; MICE, INBRED C57BL; MYELIN BASIC PROTEIN; MYELIN PROTEOLIPID PROTEIN; MYELIN SHEATH; RECOMBINANT FUSION PROTEINS; SPINAL CORD; T-LYMPHOCYTES;

EID: 84872692332     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2012.12.007     Document Type: Article

References (60)

1. Franciotta D., Salvetti M., Lolli F., Serafini B., Aloisi F. B cells and multiple sclerosis. Lancet Neurol. 2008, 7:852-858.
2. Kuerten S., Pauly R., Blaschke S., Rottlaender A., Kaiser C.C., Schroeter M., Fink G.R., Addicks K. The significance of a B cell-dependent immunopathology in multiple sclerosis. Fortschr. Neurol. Psychiatr. 2011, 79:83-91.
3. Cross A.H., Waubant E. MS and the B cell controversy. Biochim. Biophys. Acta 2011, 1812:231-238.
4. Oliver A.R., Lyon G.M., Ruddle N.H. Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice. J. Immunol. 2003, 171:462-468.
5. Pöllinger B., Krishnamoorthy G., Berer K., Lassmann H., Bösl M.R., Dunn R., Domingues H.S., Holz A., Kurschus F.C., Wekerle H. Spontaneous remitting-relapsing EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J. Exp. Med. 2009, 206:1303-1316.
6. Kuerten S., Lichtenegger F.S., Faas S., Angelov D.N., Tary-Lehmann M., Lehmann P.V. MBP-PLP fusion protein-induced EAE in C57BL/6 mice. J. Neuroimmunol. 2006, 177:99-111.
7. Elliott E.A., McFarland H.I., Nye S.H., Cofiell R., Wilson T.M., Wilkins J.A., Squinto S.P., Matis L.A., Mueller J.P. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein. J. Clin. Invest. 1996, 98:1602-1612.
8. Kuerten S., Pauly R., Rottlaender A., Rodi M., Gruppe T., Addicks K., Tary-Lehmann M., Lehmann P.V. Myelin-reactive antibodies mediate the pathology of MBP-PLP fusion protein MP4-induced EAE. Clin. Immunol. 2011, 140:54-62.
9. Lindsberg P.J., Ohman J., Lehto T., Karjalainen-Lindsberg M.L., Paetau A., Wuorimaa T., Carpén O., Kaste M., Meri S. Complement activation in the central nervous system following blood-brain barrier damage in man. Ann. Neurol. 1996, 40:587-596.
10. Lucchinetti C., Brück W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
11. Compston D.A., Morgan B.P., Campbell A.K., Wilkins P., Cole G., Thomas N.D., Jasani B. Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol. Appl. Neurobiol. 1989, 15:307-316.
12. Gay F.W., Drye T.J., Dick G.W., Esiri M.M. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 1997, 120:1461-1483.
13. Piddlesden S.J., Lassmann H., Zimprich F., Morgan B.P., Linington C. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am. J. Pathol. 1993, 555-564.
14. Kemper C., Atkinson J.P. T-cell regulation: with complements from innate immunity. Nat. Rev. Immunol. 2007, 7:9-18.
15. Heeger P.S., Lalli P.N., Lin F., Valusjskikh A., Liu J., Muqim N., Xu Y., Medof M.E. Decay-accelerating factor modulates induction of T cell immunity. J. Exp. Med. 2005, 201:1523-1530.
16. Strainic M.G., Liu J., Huang D., An F., Lalli P.N., Muqim N., Shapiro V.S., Dubyak G.R.G.R., Heeger P.S., Medof M.E. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naïve CD4+ T cells. Immunity 2008, 28:425-435.
17. Molina H., Holers V.M., Li B., Fung Y., Mariathasan S., Goellner J., Strauss-Schoenberger J., Karr R.W., Chaplin D.D. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:3357-3361.
18. Carroll M.C. The complement system in B cell regulation. Mol. Immunol. 2004, 41:141-146.
19. Calida D.M., Constantinescu C., Purev E., Zhang G.X., Ventura E.S., Lavi E., Rostami A. Cutting edge: C3, a key component of complement activation, is not required for the development of myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis in mice. J. Immunol. 2001, 166:723-726.
20. Boos L.A., Szalai A.J., Barnum S.R. Murine complement C4 is not required for experimental autoimmune encephalomyelitis. Glia 2005, 49:158-160.
21. Linington C., Morgan B.P., Scolding N.J., Wilkins P., Piddlesden S., Compston D.A.S. The role of complement in the pathogenesis of experimental allergic encephalomyelitis. Brain 1989, 112:895-911.
22. Nataf S., Carroll S.L., Wetse R.A., Szalai A.J., Barnum S.R. Attenuation of experimental autoimmune demyelination in complement-deficient mice. J. Immunol. 2000, 165:5867-5873.
23. Tran G.T., Hodgkinson S.J., Carter N., Killingsworth M., Spicer S.T., Hall B.M. Attenuation of experimental allergic encephalomyelitis in complement component 6-deficient rats is associated with reduced complement C9 deposition, P-selectin expression, and cellular infiltrate in spinal cords. J. Immunol. 2002, 168:4293-4300.
24. Szalai A.J., Hu X., Adams J.E., Barnum S.E. Complement in experimental autoimmune encephalomyelitis revisited: C3 is required for development of maximal disease. Mol. Immunol. 2007, 44:3132-3136.
25. Weerth S.H., Rus H., Shin M.L., Raine C.S. Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis. Am. J. Pathol. 2003, 163:1069-1080.
26. Niculescu T., Weerth S., Niculescu F., Cudrici C., Rus V., Raine C.S., Shin M.L., Rus H. Effects of complement C5 on apoptosis in experimental autoimmune encephalomyelitis. J. Immunol. 2004, 172:5702-5706.
27. Tegla C.A., Cudrici C., Rus V., Ito T., Vlaicu S., Singh A., Rus H. Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival. J. Neuroimmunol. 2009, 213:3-11.
28. Lyons J.A., Ramsbottom M.J., Cross A.H. Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein. Eur. J. Immunol. 2002, 32:1905-1913.
29. Ruddy S., Austen K.F., Goetzl E.J. Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B. J. Clin. Invest. 1975, 55:587-592.
30. Cochrane C.G., Müller-Eberhard H.J., Aikin B.S. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J. Immunol. 1970, 105:55-69.
31. Van den Berg C.W., Aerts P.C., Van Dijk H. Functional assay of C5-activating and nonactivating cobra venom factor preparations in the mouse system. J. Immunol. Methods 1990, 133:199-206.
32. Vogel C.W., Fritzinger D.C., Hew B.E., Thorne M., Bammert H. Recombinant cobra venom factor. Mol. Immunol. 2004, 41:191-199.
33. Javeri S., Rodi M., Tary-Lehmann M., Lehmann P.V., Addicks K., Kuerten S. Involvement of brain-derived neurotrophic factor in MP4-induced autoimmune encephalomyelitis. Clin. Immunol. 2010, 137:181-189.
34. Gruppe T.L., Recks M.S., Addicks K., Kuerten S. The extent of ultrastructural spinal cord pathology reflects disease severity in experimental autoimmune encephalomyelitis. Histol. Histopathol. 2012, 27:1163-1174.
35. Terényi N., Nagy N., Papp K., Prechl J., Oláh I., Erdei A. Transient decomplementation of mice delays onset of experimental autoimmune encephalomyelitis and impairs MOG-specific T cell response and autoantibody production. Mol. Immunol. 2009, 47:57-63.
36. Linington C., Lassmann H., Morgan B.P., Compston D.A.S. Immunohistochemical localisation of terminal complement C9 in experimental allergic encephalitis. Acta Neuropathol. 1989, 79:78-85.
37. Vanguri P., Koski C.L., Silverman B., Shin M.L. Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:3290-3294.
38. Veerhuis R., Nielsen H.M., Tenner A.J. Complement in the brain. Mol. Immunol. 2011, 48:1592-1603.
39. Seil F.J. Tissue culture studies of demyelinating disease: a critical review. Ann. Neurol. 1977, 2:345-355.
40. Liu W.T., Vanguri P., Shin M.L. Studies on demyelination in vitro: the requirement of membrane attack components of the complement system. J. Immunol. 1983, 131:778-782.
41. Scolding N.J., Morgan B.P., Compston D.A. The expression of complement regulatory proteins by adult human oligodendrocytes. J. Neuroimmunol. 1998, 84:69-75.
42. Mead R.J., Singhrao S.K., Neal J.W., Lassmann H., Morgan B.P. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J. Immunol. 2002, 168:458-465.
43. Benveniste E.N. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J. Mol. Med. 1997, 75:165-173.
44. Storch M.K., Piddlesden S., Haltia M., Iivanainen M., Morgan P., Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann. Neurol. 1998, 43:465-471.
45. Soane L., Cho H.J., Niculescu F., Rus H., Shin M.L. C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway. J. Immunol. 2001, 167:2305-2311.
46. Urich E., Gutcher I., Prinz M., Becher B. Autoantibody-mediated demyelination depends on complement activation but not activatory Fc-receptors. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:18697-18702.
47. Chen A., Gaddipati S., Hong Y., Volkman D.J., Peerschke E.I., Ghebrehiwet B. Human T cells express specific binding sites for C1q. Role in T cell activation and proliferation. J. Immunol. 1994, 153:1430-1440.
48. Kwan W.H., van der Touw W., Heeger P.S. Complement regulation of T cell immunity. Immunol. Res. 2012, 54:247-253.
49. Piddlesden S., Lassmann H., Laffafian I., Morgan B.P., Linington C. Antibody-mediated demyelination in experimental allergic encephalitis is independent of complement membrane attack complex formation. Clin. Exp. Immunol. 1991, 83:245-250.
50. Lalli P.N., Strainic M.G., Yang M., Lin F., Medof M.E., Heeger P.S. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 2008, 112:1759-1766.
51. Liu J., Miwa T., Hilliard B., Chen Y., Lambris J.D., Wells A.D., Song W.C. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J. Exp. Med. 2005, 201:567-577.
52. Lalli P.N., Strainic M.G., Lin F., Medof M.E., Heeger P.S. Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production. J. Immunol. 2007, 179:5793-5802.
53. Li K., Anderson K.J., Peng Q., Noble A., Lu B., Kelly A.P., Wang N., Sacks S.H., Zhou W. Cyclic AMP plays a critical role in C3a receptor-mediated regulation of dendritic cells in antigen uptake and T-cell stimulation. Blood 2008, 112:5084-5094.
54. Liu J., Lin F., Strainic M.G., An F., Miller R.H., Altuntas C.Z., Heeger P.S., Tuohy V.K., Medof M.E. IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production. J. Immunol. 2008, 180:5882-5889.
55. Carter R.H., Spycher M.O., Ng Y.C., Hoffman R., Fearon D.T. Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J. Immunol. 1988, 141:457-463.
56. Fearon D.T., Carter R.H. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu. Rev. Immunol. 1995, 13:127-149.
57. Dempsey P.W., Allison M.E., Akkaraju S., Goodnow C.C., Fearon D.T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996, 271:348-350.
58. Lyubchenko T., Dal Porto J.M., Holers V.M., Cambier J.C. Cutting edge: complement (C3d)-linked antigens break B cell anergy. J. Immunol. 2007, 179:2695-2699.
59. Bastista F.D., Arana E., Barral P., Carrasco Y.R., Depoil D., Eckl-Dorna J., Fleire S., Howe K., Vehlow A., Weber M., Treanor B. The role of integrins and coreceptors in refining threshold for B-cell responses. Immunol. Rev. 2007, 218:197-213.
60. Pekkarinen P.T., Vaali K., Junnikkala S., Rossi L.H., Tuovinen H., Meri S., Vaarala O., Arstila T.P. A functional complement system is required for normal T helper cell differentiation. Immunobiology 2011, 216:737-743.